- Deerfield wins sweetened bid to acquire NitroMed
- Vertex raises $25M in IPO to fund collaboration w/Chugai
- Vertex nets $313.6mm to support hepatitis and CF candidates
- J&J gets rights to Vertex's VX950 for HCV; Janssen buys royalty rights
- Mitsubishi gets rights to Vertex's VX-950 for hepatitis C
- Vertex acquires ViroChem in cash and stock transaction
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.